Minimal Survival Differences Among RT Modalities for Intermediate-Risk PCa
In a study, brachytherapy was associated with only a slight survival advantage over dose-escalated EBRT.
Prostate Cancer
Greater Subcutaneous Fat Improves mCRPC Treatment Response
In a study of men with mCRPC receiving chemotherapy and maximal androgen ablation, those who had an objective response to treatment had a significantly higher subcutaneous adipose tissue index than those who did not.
With Rucaparib Approval, Prostate Cancer Joins the Precision Oncology Era
The FDA’s accelerated approval of the PARP inhibitor rucaparib brings clinical prostate oncology into the precision medicine era.
Earlier Surrogate for Survival After RP Relapse Possibly Identified
Castration-resistant prostate cancer correlates strongly with development of metastasis in men with PSA relapse following radical surgery for localized prostate cancer, but it occurs much sooner, and thus may provide an intermediate endpoint in clinical trials of new therapeutics.
PARP Inhibitor Prolongs Overall Survival in mCRPC
An overall survival advantage with olaparib was particularly observed among patients with BRCA1 or BRCA2 alterations.
HIFU Focal Ablation for PCa Offers Adequate Short-Term Cancer Control
In a study, men who underwent high-intensity focused ultrasound partial gland ablation for prostate cancer had excellent preservation of potency and continence.
Darolutamide Prolongs Overall Survival in nmCRPC
Darolutamide also improved secondary endpoints, including the time to pain progression, cytotoxic chemotherapy, and first symptomatic skeletal event.
Factors Clarify Racial Disparity in Prostate Cancer Survival
Education, median household income, and insurance status contribute most to racial disparity in the US.
Doubling of Radical Surgery Rates for High-Risk Prostate Cancer Reported
By 2016, radical prostatectomy use nearly equaled radiation therapy use for high-risk prostate cancer.
Oral Antiandrogens Found to Increase Dementia Risk
In a study, only androgen deprivation therapy with oral antiandrogens were associated with an increased risk for dementia and Alzheimer disease.
-
Loading...
-
Loading...
Next post in Prostate Cancer
